New depression drug GM-2505 enters Mid-Stage trial

NCT ID NCT06236880

Recruiting now Symptom relief Sponsor: Gilgamesh Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called GM-2505 in people with major depressive disorder. Participants receive two doses of the drug two weeks apart. The study has three parts: one for people not on antidepressants, one for those partially responding to current treatment, and one to confirm earlier findings. The main goal is to check safety and tolerability, with early signs of antidepressant effect also measured.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GM-2505 (an experimental drug given intravenously)
What this could lead to: If it works, this could point toward a new treatment option for people with major depressive disorder who are not responding well to current antidepressants.
What could go wrong: This is an early Phase 2a study with only 124 participants, so results may not apply to everyone. The drug is still experimental, and its safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

MAC Clinical Research
RECRUITING

Manchester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.